MedTrace Logo

Weight Loss in Adults Using Semaglutide (Real-world Study)

NCT07627074 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 35000

Last updated 2026-06-04

No results posted yet for this study

Summary

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Conditions

Interventions

DRUG

Semaglutide

This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-12
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07627074 on ClinicalTrials.gov